Retraction of: npj Precision Oncology https://doi.org/10.1038/s41698-017-0008-z, published online 03 April 2017
This Article1 has been retracted by the Authors because concerns have been raised regarding the identity of the cell lines used for the experimental work. Specifically, re-analysis showed that the S1GODL xenografts matched STR profiles of Ovcar-3 cells, and review of raw flow cytometry data was found to be discordant with presented data. In light of these findings, the identity of the cells within the experimental groups in the manuscript is uncertain, and the conclusions of the work are not reliable.
Authors Vincent La, Rachel Fujikawa, Deanna Janzen, Miguel Nunez, Lin Hwang, Kym Faull, Greg Lawson, and Sanaz Memarzadeh agree with this attraction. Liat Bainvoll did not respond to correspondence from the Publisher about this retraction.
Reference
La, V. et al. Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. npj Precision Onc. 1, 7, https://doi.org/10.1038/s41698-017-0008-z (2017).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
La, V., Fujikawa, R., Janzen, D.M. et al. Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. npj Precis. Onc. 5, 77 (2021). https://doi.org/10.1038/s41698-021-00217-9
Published:
DOI: https://doi.org/10.1038/s41698-021-00217-9
